Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer

被引：9
作者：
Messori, Andrea [1 ]
De Rosa, Mauro [2 ]
Fadda, Valeria [3 ]
Pani, Luca [4 ]
机构：
[1] ESTAR Toscana, Reg Hlth Serv, Florence, Italy
[2] Italian Soc Clin Pharm & Therapeut, Milan, Italy
[3] ESTAR Toscana, Reg Hlth Serv, Florence, Italy
[4] AIFA Italian Med Agcy, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 32期
关键词：
RECURRENT OVARIAN-CANCER; OPEN-LABEL; WEEKLY PACLITAXEL; DOUBLE-BLIND; PHASE-II; CARBOPLATIN; MULTICENTER;
D O I：
10.1200/JCO.2015.61.8991
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3838 / +
页数：3
相关论文
共 10 条
  • [1] Chan J, 2013, INT J GYNECOL CANCER, V23
  • [2] Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
    Karlan, Beth Y.
    Oza, Amit M.
    Richardson, Gary E.
    Provencher, Diane M.
    Hansen, Vincent L.
    Buck, Martin
    Chambers, Setsuko K.
    Ghatage, Prafull
    Pippitt, Charles H., Jr.
    Brown, John V., III
    Covens, Allan
    Nagarkar, Raj V.
    Davy, Margaret
    Leath, Charles A., III
    Hoa Nguyen
    Stepan, Daniel E.
    Weinreich, David M.
    Tassoudji, Marjan
    Sun, Yu-Nien
    Vergote, Ignace B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 362 - 371
  • [3] Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
    Katsumata, Noriyuki
    Yasuda, Makoto
    Isonishi, Seiji
    Takahashi, Fumiaki
    Michimae, Hirofumi
    Kimura, Eizo
    Aoki, Daisuke
    Jobo, Toshiko
    Kodama, Shoji
    Terauchi, Fumitoshi
    Sugiyama, Toru
    Ochiai, Kazunori
    [J]. LANCET ONCOLOGY, 2013, 14 (10) : 1020 - 1026
  • [4] Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
    Lortholary, A.
    Largillier, R.
    Weber, B.
    Gladieff, L.
    Alexandre, J.
    Durando, X.
    Slama, B.
    Dauba, J.
    Paraiso, D.
    Pujade-Lauraine, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (02) : 346 - 352
  • [5] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Miller, Kathy
    Wang, Molin
    Gralow, Julie
    Dickler, Maura
    Cobleigh, Melody
    Perez, Edith A.
    Shenkier, Tamara
    Cella, David
    Davidson, Nancy E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) : 2666 - 2676
  • [6] Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
    Monk, Bradley J.
    Poveda, Andres
    Vergote, Ignace
    Raspagliesi, Francesco
    Fujiwara, Keiichi
    Bae, Duk-Soo
    Oaknin, Ana
    Ray-Coquard, Isabelle
    Provencher, Diane M.
    Karlan, Beth Y.
    Lhomme, Catherine
    Richardson, Gary
    Rincon, Dolores Gallardo
    Coleman, Robert L.
    Herzog, Thomas J.
    Marth, Christian
    Brize, Arija
    Fabbro, Michel
    Redondo, Andres
    Bamias, Aristotelis
    Tassoudji, Marjan
    Navale, Lynn
    Warner, Douglas J.
    Oza, Amit M.
    [J]. LANCET ONCOLOGY, 2014, 15 (08) : 799 - 808
  • [7] Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
    Pignata, Sandro
    Scambia, Giovanni
    Katsaros, Dionyssios
    Gallo, Ciro
    Pujade-Lauraine, Eric
    De Placido, Sabino
    Bologna, Alessandra
    Weber, Beatrice
    Raspagliesi, Francesco
    Panici, Pierluigi Benedetti
    Cormio, Gennaro
    Sorio, Roberto
    Cavazzini, Maria Giovanna
    Ferrandina, Gabriella
    Breda, Enrico
    Murgia, Viviana
    Sacco, Cosimo
    Cinieri, Saverio
    Salutari, Vanda
    Ricci, Caterina
    Pisano, Carmela
    Greggi, Stefano
    Lauria, Rossella
    Lorusso, Domenica
    Marchetti, Claudia
    Selvaggi, Luigi
    Signoriello, Simona
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Perrone, Francesco
    [J]. LANCET ONCOLOGY, 2014, 15 (04) : 396 - 405
  • [8] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David
    Ray-Coquard, Isabelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1302 - +
  • [9] Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
    Sehouli, Jalid
    Stengel, Dirk
    Harter, Philipp
    Kurzeder, Christian
    Belau, Antje
    Bogenrieder, Thomas
    Markmann, Susanne
    Mahner, Sven
    Mueller, Lothar
    Lorenz, Ralf
    Nugent, Andreas
    Wilke, Jochen
    Kuznik, Andreas
    Doering, Gabriele
    Wischnik, Arthur
    Sommer, Harald
    Meerpohl, Hans-Gerd
    Schroeder, Willibald
    Lichtenegger, Werner
    Oskay-Oezcelik, Guelten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 242 - 248
  • [10] Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
    Stockler, Martin R.
    Hilpert, Felix
    Friedlander, Michael
    King, Madeleine T.
    Wenzel, Lari
    Lee, Chee Khoon
    Joly, Florence
    de Gregorio, Nikolaus
    Angel Arranz, Jose
    Mirza, Mansoor Raza
    Sorio, Roberto
    Freudensprung, Ulrich
    Sneller, Vesna
    Hales, Gill
    Pujade-Lauraine, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1309 - +
1